Specify a stock or a cryptocurrency in the search bar to get a summary
Clearside Biomedical Inc
CLSDClearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. Clearside Biomedical, Inc. has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. The company was incorporated in 2011 and is headquartered in Alpharetta, Georgia. Address: 900 North Point Parkway, Alpharetta, GA, United States, 30005
Analytics
WallStreet Target Price
5.67 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures CLSD
Dividend Analytics CLSD
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History CLSD
Stock Valuation CLSD
Financials CLSD
Results | 2019 | Dynamics |